v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Revenue $ 73,400 $ 68,914 $ 137,579 $ 147,939
Operating expenses:        
Cost of revenue 38,271 43,273 76,606 76,949
Selling, general and administrative 40,556 35,377 81,441 74,048
Research and development 5,284 4,194 10,316 8,339
Change in estimated fair value of contingent consideration (1,195) (2,316) (1,195) (2,316)
Restructuring (4) 0 (1,216) 0
Total operating expenses 82,912 80,528 165,952 157,020
Loss from operations (9,512) (11,614) (28,373) (9,081)
Other income (expense):        
Interest expense (11,939) (7,022) (22,803) (18,855)
Interest income 7,086 6,791 14,296 12,836
Change in payable to related parties pursuant to the Tax Receivable Agreement 0 101 0 (1,335)
Other expense (2,562) (1,620) (2,456) (1,452)
Loss before income taxes (16,927) (13,364) (39,336) (17,887)
Income tax benefit (2,435) (1,421) (2,164) (4,596)
Net loss (14,492) (11,943) (37,172) (13,291)
Net loss attributable to non-controlling interests (6,907) (5,402) (17,509) (6,683)
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (7,585) $ (6,541) $ (19,663) $ (6,608)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share) $ (0.05) $ (0.05) $ (0.15) $ (0.05)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share) $ (0.05) $ (0.05) $ (0.15) $ (0.05)
Weighted average number of Class A common shares outstanding, basic (in shares) 135,842 131,864 134,088 131,802
Weighted average number of Class A common shares outstanding, diluted (in shares) 135,842 131,864 134,088 131,802

Source